Additional Hetero Atom In The Polycyclo Ring System Patents (Class 514/215)
-
Publication number: 20110071136Abstract: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.Type: ApplicationFiled: September 16, 2010Publication date: March 24, 2011Applicant: CYLENE PHARMACEUTICALS, INCInventors: Mustapha HADDACH, Fabrice PIERRE
-
Publication number: 20110071135Abstract: There is described a method for increasing the maximal tolerated close and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT3 receptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholine esterase inhibitor are also described.Type: ApplicationFiled: September 13, 2010Publication date: March 24, 2011Applicant: CHASE PHARMACEUTICALS CORPORATIONInventors: Thomas N. CHASE, Kathleen E. Clarence-Smith
-
Publication number: 20110064804Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.Type: ApplicationFiled: April 9, 2010Publication date: March 17, 2011Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz
-
Publication number: 20110065628Abstract: The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention provides compositions and methods for treating disorders using combinations of drugs such as topiramate, ondansetron, and naltrexone.Type: ApplicationFiled: May 20, 2008Publication date: March 17, 2011Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Bankole A. Johnson, Nassima Ait-Daoud Tiouririne, Wendy J. Lynch
-
Publication number: 20110059948Abstract: The invention relates to a compound of general formula I, II, III, IV, V, VI, VII, VIII, IX, X or a tautomer and the stereochemically isomeric forms thereof or pharmaceutically acceptable salts thereof, a N-oxide form thereof or a pro-drug thereof. The compound is usable as a medicament for the treatment of mycobacterial disease.Type: ApplicationFiled: January 9, 2009Publication date: March 10, 2011Inventors: Jyoti Chattopadhyaya, Ram Shankar Upadhayaya
-
Publication number: 20110059905Abstract: Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.Type: ApplicationFiled: March 31, 2009Publication date: March 10, 2011Inventors: Theresa A. Zesiewicz, Kelly L. Sullivan
-
Publication number: 20110059141Abstract: Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug.Type: ApplicationFiled: November 17, 2010Publication date: March 10, 2011Inventor: Takeshi Ito
-
Patent number: 7897595Abstract: The present invention relates to pyridoazepine derivatives that act as 5-HT ligands, e.g., 5-HT2 C. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.Type: GrantFiled: May 23, 2007Date of Patent: March 1, 2011Assignee: Forest Laboratories Holdings LimitedInventors: Gian-Luca Araldi, Alexander Bischoff, Nhut K. Diep
-
Patent number: 7893051Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).Type: GrantFiled: January 17, 2007Date of Patent: February 22, 2011Assignee: Athersys, Inc.Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
-
Publication number: 20110039825Abstract: The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously ?-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C1-C4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, CF3, CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH2)m group, optionally substituted CH?CH group, optionally substType: ApplicationFiled: December 19, 2008Publication date: February 17, 2011Applicant: Alla Chem, LLCInventors: Andrey Alexandrovich Ivashchenko, Vasilievich Ivashchenko, Yan Vadimovich Lavrovsky, Oleg Dmitrievich Mitkin, Nikolay Filippovich Savchuk, Sergey Yevgenievich Tkachenko, Ilya Matusovich Okun
-
Publication number: 20110039824Abstract: Provided are certain 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate compounds which are useful for modulating the activity of nuclear receptors, such as farnesoid X receptors, and/or for the treatment, prevention, or amelioration diseases or disorders related to the activity of these receptors.Type: ApplicationFiled: May 13, 2010Publication date: February 17, 2011Applicant: WyethInventors: Joseph Theodore Lundquist, IV, Paige Erin Mahaney, Callain Younghee Kim, Matthew Lantz Crawley
-
Publication number: 20110039826Abstract: This invention provides novel pharmaceutical compositions of the compound of formula (I): or a pharmaceutically acceptable salt thereof, that are suitable for the bulk production of an oral pharmaceutical dosage form; processes for the production of said oral pharmaceutical dosage form; and the use of the pharmaceutical composition for the treatment of patients suffering from or subject to diseases, disorders, or conditions involving cell survival, proliferation and migration, including chronic inflammatory proliferative disorders, proliferative ocular disorders, benign proliferative disorders, and cancer.Type: ApplicationFiled: July 28, 2010Publication date: February 17, 2011Applicant: Millennium Pharmaceuticals, Inc.Inventors: Vijayalakshmi Ramanan, Irene S. Tobias, Raymond D. Skwierczynski, Dauntel S. Verwijs
-
Patent number: 7888346Abstract: A method of treating organophosphorous (OP) poisoning comprising administering to a mammal at risk for OP poisoning an OP poisoning-inhibiting amount of galantamine.Type: GrantFiled: September 23, 2005Date of Patent: February 15, 2011Assignee: Universtiy of Maryland, BaltimoreInventors: Edson X. Albuquerque, Michael Adler, Edna F. R. Pereira
-
Patent number: 7888347Abstract: The present invention relates to novel pyrazole derivatives of formula I having pharmacological activity as H3 antagonists processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.Type: GrantFiled: July 4, 2006Date of Patent: February 15, 2011Assignee: Glaxo Group LimitedInventors: Mark James Bamford, David Matthew Wilson
-
Publication number: 20110033461Abstract: Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.Type: ApplicationFiled: March 12, 2009Publication date: February 10, 2011Inventors: Vladimir Ratushny, Erica Golemis, Igor Astsaturov, Iiya G. Serebriiskii, Louis M. Weiner
-
Publication number: 20110021503Abstract: There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-selective, peripheral anticholinergic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent.Type: ApplicationFiled: March 17, 2009Publication date: January 27, 2011Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
-
Publication number: 20110021502Abstract: The invention discloses the use of cholinesterase inhibitors in treating vascular depression.Type: ApplicationFiled: August 25, 2010Publication date: January 27, 2011Inventor: Roger Michael LANE
-
Publication number: 20110021493Abstract: This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.Type: ApplicationFiled: September 2, 2008Publication date: January 27, 2011Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Hartmut Schirok, Ying Li-Sommer, Michael Brands, Mario Lobell, Adrian Tersteegen, Herbert Himmel, Karl-Heinz Schlemmer, Dieter Lang, Kirsten Petersen, Matthias Renz, Dominik Mumberg, Jens Hoffman, Gerhard Siemeister, Ulf Bömer
-
Publication number: 20110015179Abstract: Disclosed herein is a pharmaceutical composition comprising a cholinesterase inhibitor and compound of the following formula: The composition is effective for treating cognitive disorders, and methods of treating such disorders using the composition are also disclosed.Type: ApplicationFiled: July 16, 2010Publication date: January 20, 2011Applicant: Allergan, Inc.Inventors: Ursula V. Staubli, John E. Donello
-
Publication number: 20110008398Abstract: Provided is a medicated patch containing a medicinal agent and an adhesive base material and having an acid value of no greater than 28, where the medicinal agent is varenicline or a pharmaceutically acceptable salt of varenicline.Type: ApplicationFiled: February 9, 2009Publication date: January 13, 2011Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Kumi Morimoto, Akio Takeuchi, Takashi Yasukochi, Kaori Yamaguchi, Kenji Ishigaki
-
Publication number: 20110003793Abstract: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.Type: ApplicationFiled: July 1, 2010Publication date: January 6, 2011Applicant: ALBANY MOLECULAR RESEARCH, INC.Inventors: Peter R. Guzzo, Matthew David Surman, James Francis Grabowski, JR., Emily Elizabeth Freeman
-
Publication number: 20100331311Abstract: The present invention relates to the use of galantamine for neuroprotection of retinal ganglion cells.Type: ApplicationFiled: September 10, 2010Publication date: December 30, 2010Inventor: Adriana Di Polo
-
Publication number: 20100324024Abstract: The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.Type: ApplicationFiled: February 3, 2009Publication date: December 23, 2010Applicant: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Ronald K. Chang, Christina Ng Di Marco
-
Publication number: 20100311642Abstract: The combination of vasopressin V2 receptor antagonists and vasopressin receptor agonists (selective or non-selective) is described, including pharmaceutical compositions, including kits, for administering, and methods and uses of such a combination, e.g. for treatment of critical care diseases and conditions requiring control of arterial blood pressure or for treatment of hypotension.Type: ApplicationFiled: September 25, 2008Publication date: December 9, 2010Applicant: Ferring B.V.Inventors: Pierre J-m.Riviere, Sudar Alagarsamy, Claudio Daniel Schteingart, Regent Laporte
-
Publication number: 20100311726Abstract: The present invention relates to novel uses for a family of small molecules, Differentiation-Inducing Factors (DIFs). It has been discovered that DIFs surprisingly can alter the metabolic processing of amyloid precursor protein (APP) and in turn reduce the level of secreted A?. The metabolic processing of other ?-secretase substrates normally present in cells (Notch and APLP1) is not affected when treated with DIF. The invention provides methods for reducing A? production in mammalian cells that express APP by administering DIF-I, DIF-2, DIF-3, a functionally equivalent analog and or any combination thereof. The invention also provides methods for treating and/or preventing Alzheimer's disease by preferentially reducing A? production.Type: ApplicationFiled: July 16, 2008Publication date: December 9, 2010Inventors: Michael Myre, Wilma Wasco, Rudolph E. Tanzi
-
Publication number: 20100311697Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.Type: ApplicationFiled: April 2, 2010Publication date: December 9, 2010Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz
-
Publication number: 20100305102Abstract: The invention relates to new dihydrothienopyrimidinesulphoxides of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings stated in claim 1, as well as pharmaceutical compositions which contain these compounds. These new dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.Type: ApplicationFiled: October 16, 2008Publication date: December 2, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Pascale Pouzet, Ralf Anderskewitz, Horst Dollinger, Dennis Fiegen, Thomas Fox, Rolf Goeggel, Christoph Hoenke, Domnic Martyres, Peter Nickolaus, Klaus Klinder
-
Publication number: 20100298278Abstract: The invention relates to the substituted 1,2-ethylenediamines of general formula (I), wherein the groups R1 to R13, A, B, L and i are defined as in the description and the claims. The invention also relates to the use thereof in the treatment of Alzheimer's disease (AD) and similar diseases.Type: ApplicationFiled: August 8, 2006Publication date: November 25, 2010Inventors: Christian Eickmeier, Klaus Fuchs, Niklas Heine, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
-
Publication number: 20100298221Abstract: The present invention relates to novel 2-phenoxy-6-phenyl- and 2-phenoxy-6-pyridylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, especially of dyslipidemias, arteriosclerosis and heart failure.Type: ApplicationFiled: August 30, 2007Publication date: November 25, 2010Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Heinrich Meier, Peter kolkhof, Axel Kretschmer, Arounarith Tuch, Lars Barfacker, Yolanda Cancho Grande
-
Publication number: 20100292188Abstract: The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals.Type: ApplicationFiled: January 22, 2009Publication date: November 18, 2010Applicant: UCB PHARMA S.A.Inventors: Frédéric Denonne, Sylvain Celanire, Anne Valade, Sabine Defays, Véronique Durieu
-
Publication number: 20100292203Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.Type: ApplicationFiled: January 26, 2010Publication date: November 18, 2010Inventors: Zhaoning Zhu, Brian McKittrick, Zhong-Yue Sun, Yuanzan C. Ye, Johannes H. Voigt, Corey O. Strickland, Elizabeth M. Smith, Andrew Stamford, William J. Greenlee, Robert D. Mazzola, John P. Caldwell, Jared N. Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Xiaoxiang Liu, Dawit Tadesse, Ying Huang, Guoqing Li, Jianping Pan
-
Publication number: 20100286123Abstract: This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.Type: ApplicationFiled: April 27, 2010Publication date: November 11, 2010Inventors: Alexander Pasternak, Aurash Shahripour, Haifeng Tang, Nardos H. Teumelsan, Lihu Yang, Yuping Zhu, Shawn P. Walsh
-
Publication number: 20100273776Abstract: Compounds and compositions are provided for treatment or amelioration of one or more symptoms of ?-synuclein toxicity, ?-synuclein mediated diseases or diseases in which ?-synuclein fibrils are a symptom or cause of the disease.Type: ApplicationFiled: March 29, 2007Publication date: October 28, 2010Applicants: FOLDRx PHARMACEUTICALS, INC, WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Susan L. Lindquist, Tiago Outeiro, Richard Labaudinière, James Fleming, Christine Ellen Bulawa, Charlotte Weigel, Feng Liang, Sandeep Gupta, Amy Ripka
-
Publication number: 20100249107Abstract: This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms associated with the conversion from Mile Cognitive Impairment to dementia, e.g., Alzheimer's Disease (AD). The invention provides AD-associated mutations which are useful in the diagnosis, prognosis or therapeutic treatment of dementia, e.g., Alzheimer's Disease.Type: ApplicationFiled: August 17, 2007Publication date: September 30, 2010Inventor: Jonathan Benjamin Singer
-
Publication number: 20100249108Abstract: The present invention relates to substituted dipyrido-pyrimido-diazepine compounds, substituted benzo-pyrido-pyrimido-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted dipyrido-pyrimido-diazepine compounds, substituted benzo-pyrido-pyrimido-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.Type: ApplicationFiled: March 31, 2010Publication date: September 30, 2010Applicant: ArQule, Inc.Inventors: Manish Tandon, Yanbin Liu, Nivedita Namdev, Mark A. Ashwell, Rocio Palma
-
Publication number: 20100249109Abstract: The present invention relates to substituted tetrahydropyrazolo-pyrido-azepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted tetrahydropyrazolo-pyrido-azepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.Type: ApplicationFiled: March 31, 2010Publication date: September 30, 2010Applicant: ArQule, Inc.Inventors: Jean-Marc Lapierre, Rui-Yang Yang, Nivedita Namdev, Jeffrey S. Link
-
Publication number: 20100249099Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.Type: ApplicationFiled: March 26, 2010Publication date: September 30, 2010Applicant: Pathway Therapeutics LimitedInventors: Gordon William Rewcastle, Swarnalatha Akuratiya Gamage, Jack Urquhart Flanagan, Anna Claire Giddens, Kit Yee Tsang
-
Publication number: 20100249110Abstract: The present invention relates to substituted pyrazolo-pyrimidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted pyrazolo-pyrimidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.Type: ApplicationFiled: March 31, 2010Publication date: September 30, 2010Applicant: ArQule, Inc.Inventors: Manish Tandon, Jianqiang Wang, Nivedita Namdev
-
Publication number: 20100240637Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Y, Q and Z have defined meanings.Type: ApplicationFiled: September 18, 2008Publication date: September 23, 2010Applicant: JANSSEN PHARMACEUTICAL NVInventors: Virginie Sophie Poncelet, Sophie Coupa, Pierre-Henri Storck, Bruno Schoentjes
-
Publication number: 20100239563Abstract: The invention relates to the use of at least one active substance for producing a pharmaceutical composition for the prophylaxis and/or treatment of at least one viral disease. It is characterized by active substance(s) which inhibit(s) either at least two kinases or at least one SEK kinase of a cellular signal transmission path such that virus multiplication is inhibited.Type: ApplicationFiled: December 23, 2008Publication date: September 23, 2010Inventors: Stephan Ludwig, Oliver Planz, Hans-Harald Sedlacek, Stephan Pleschka
-
Publication number: 20100234349Abstract: This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.Type: ApplicationFiled: September 4, 2007Publication date: September 16, 2010Inventors: Gunnar M. Olsen, Dan Peters, Bjarne H. Dahl, Jeppe Kejser Christensen, Steven Charles Loechel, Daniel B. Timmermann
-
Publication number: 20100233304Abstract: Compositions comprising one or more unsaturated fatty acids and one or more nitric oxide releasing compounds, and methods for using such compositions for enhancing cognitive function, reducing or preventing a decline of social interaction, reducing or preventing age-related behavioral changes, increasing trainability, maintaining optimal brain function, facilitating learning and memory, reducing memory loss, retarding brain aging, preventing or treating strokes, and preventing or treating dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.Type: ApplicationFiled: December 19, 2008Publication date: September 16, 2010Inventor: Yuanlong Pan
-
Publication number: 20100234351Abstract: A compound of the formula: wherein ring A is a 7-membered or 8-membered nitrogen-containing ring optionally further substituted, ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group, X1 is a group represented by —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 may be bonded to the carbon atom of ring B to form an optionally substituted ring structure, and Y1 is a bond or an optionally substituted alkylene, R1 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, the formula shows a single bond or a double bond, when R2 is —R2, R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and when R2 is ?R2, R2 is an oxo group, an optionally substituted alkylidene group, or an optionally substituted imino group.Type: ApplicationFiled: February 22, 2007Publication date: September 16, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masaki Seto, Tomohiro Ohashi
-
Publication number: 20100227852Abstract: The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.Type: ApplicationFiled: March 22, 2010Publication date: September 9, 2010Applicant: MERZ PHARMA GmbH & CO. KGaAInventor: Hans-Joerg Moebius
-
Publication number: 20100227844Abstract: The present invention relates to methods of treating Alzheimer's Disease and Alzheimer's Disease related disorders comprising administration of a compound of structural formula: (I), or a pharmaceutically acceptable salt thereof, as a monotherapy or in combination with an anti-Alzheimer's Disease agent. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.Type: ApplicationFiled: October 20, 2008Publication date: September 9, 2010Inventors: Tung M. Fong, Leonardus H.T. Van Der Ploeg
-
Patent number: 7790710Abstract: The compounds of formula (I) in which R1, R11 and A have the meanings as given in the description are novel effective iNOS inhibitors.Type: GrantFiled: March 29, 2006Date of Patent: September 7, 2010Assignee: NYCOMED GmbHInventors: Thomas Fuchss, Andreas Strub, Wolf-Rüdiger Ulrich, Christian Hesslinger, Martin Lehner, Raimund Külzer, Rainer Boer, Manfrid Eltze
-
Publication number: 20100222316Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.Type: ApplicationFiled: March 17, 2010Publication date: September 2, 2010Applicant: ABBOTT LABORATORIESInventors: Marina A. Pliushchev, Dariusz Wodka, Bryan K. Sorensen, James T. Link
-
Publication number: 20100215740Abstract: The present invention relates to a solid pharmaceutical composition comprising memantine, which dissolves or disintegrates in the oral cavity preferably within about 60 seconds. The present invention further discloses orally disintegrating tablets of taste-masked memantine of optimal mechanical strength comprising memantine along with a taste-masking agent and pharmaceutically acceptable excipients.Type: ApplicationFiled: October 10, 2008Publication date: August 26, 2010Applicant: Rubicon Research Private LimitedInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi
-
Publication number: 20100216775Abstract: This invention concerns adamantanamines (e.g. memantine, amantadine, and rimantadine) and neramexane salts of thiomolybdic and thiotungstic acids, including their preparation and pharmaceutical compositions, as dual acting drugs. These salts are used to treat or potentially arrest the neurodegenerative pathophysiology, clinical signs and symptoms of dementia of the Alzheimer's type, Parkinson's, Huntington's, AIDS-related dementia and Schizophrenia and its cognitive deficits. Additional uses of these derivatives include antiviral activity.Type: ApplicationFiled: February 21, 2008Publication date: August 26, 2010Applicant: SSV TherapeuticsInventor: Om P. Goel
-
Publication number: 20100215774Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin and/or other active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: February 8, 2008Publication date: August 26, 2010Inventor: Todd Maibach